Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis

Jun Ba, Run-Sheng Peng, Ding Xu, Yan-Hong Li, Hui Shi, Qianyi Wang, Jing Yu, Jun Ba, Run-Sheng Peng, Ding Xu, Yan-Hong Li, Hui Shi, Qianyi Wang, Jing Yu

Abstract

Aims: Age-related macular degeneration (AMD) is the main cause of blindness. Anti-vascular endothelial growth factor is used to prevent further neovascularization due to wet AMD. The purpose of this systematic review was to investigate the effect and protocol of anti-vascular endothelial growth factor treatment on wet AMD.

Methods: A comprehensive literature search was performed in PubMed, Embase, the Cochrane Library, CNKI, and reference lists. Meta-analysis was performed using Stata12.0 software, best corrected visual acuity (BCVA), retinal thickness, and lesion size were evaluated.

Results: Twelve randomized controlled trials spanning from 2010 to 2014 and involving 5,225 patients were included. A significant difference was observed between the intravitreal ranibizumab (IVR) group and the intravitreal bevacizumab group (standard mean difference = -0.14, 95% confidence interval [CI] = -0.23 to -0.05). No significant differences were observed in best corrected VA, retinal thickness, or lesion size between IVR and the intravitreal aflibercept group. Compared to monthly injection, IVR as-needed injections (PRN) can raise VA by 1.97 letters (weighted mean difference = 1.97, 95% CI = 0.14-3.794). Combination therapy of IVR and photodynamic therapy can significantly raise VA by 2.74 letters when combined with IVR monotherapy (weighted mean difference = 2.74, 95% CI = 0.26-5.21).

Conclusion: The superiority remains unclear between IVR and intravitreal bevacizumab in the treatment of neovascular AMD. Intravitreal aflibercept dosed every 2 months required fewer injection times, but produced similar efficacy as monthly IVR. IVR PRN could significantly increase VA. Combined with photodynamic therapy, IVR therapy could also increase VA effectively.

Keywords: VEGF; aflibercept; age-related macular degeneration; bevacizumab; meta-analysis; ranibizumab.

Figures

Figure 1
Figure 1
Search strategy flow diagram regarding anti-VEGF agents for treating wet AMD. Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularization; RCT, randomized controlled trial; VEGF, vascular endothelial growth factor.
Figure 2
Figure 2
Forest plot of BCVA of IVR vs IVB for treating wet AMD. Note: No significant difference was observed between the IVR group and the IVB group. Abbreviations: AMD, age-related macular degeneration; BCVA, best corrected visual acuity; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; WMD, weighted mean difference; CI, confidence interval.
Figure 3
Figure 3
Forest plot of BCVA of monthly IVR vs PRN for treating wet AMD. Notes: A significant difference was shown between the two groups. Compared to monthly injection, PRN treatment can raise VA by 1.97 letters (WMD =1.97, 95% CI =0.14–3.794, P=0.04). Abbreviations: AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CI, confidence interval; IVR, intravitreal ranibizumab; PRN, injection as-needed; WMD, weighted mean difference; VA, visual acuity.
Figure 4
Figure 4
Forest plot of BCVA of IVR monotherapy vs IVR+PDT for treating wet AMD. Notes: A significant difference was shown between the two groups. Compared to monotherapy, the combination therapy can raise VA by 2.74 letters (WMD =2.74, 95% CI =0.26–5.21, P=0.03). Abbreviations: AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CI, confidence interval; IVR, intravitreal ranibizumab; PDT, photodynamic therapy; WMD, weighted mean difference; VA, visual acuity.

References

    1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67–115.
    1. Friedman DS, O’Colmain BJ, Mufioz B, et al. Eye Diseases Prevalence Research Group: prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572.
    1. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians- a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921–927.
    1. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration- a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–126.
    1. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:495–501.
    1. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2(2):377–388.
    1. Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816.
    1. Cruess AF, Berger A, Colleaux K, et al. Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Can J Ophthalmol. 2012;47(3):227–235.
    1. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222–226.
    1. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial. 1996;17(1):1–12.
    1. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority ranibizumab trial. Ophthalmology. 2013;120(11):2300–2309.
    1. Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmologica. 2013;91(3):e178–e183.
    1. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992–1000.
    1. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–1411.
    1. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 2010;24(11):1708–1715.
    1. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24(10):1561–1567.
    1. Busbee BG, Ho AC, Brown DM, et al. HARBOR Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056.
    1. Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
    1. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001–1010.
    1. Williams PD, Callanan D, Solley W, Avery RL, Piramici DJ, Aaberg T. A prospective pilot study comparing combined intravitreal ranibizumab and half-influence photodynamic therapy with ranibizumab in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2012;6:1529–1525.
    1. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
    1. Krebs I, Schmetterer L, Boltz A, et al. MANTA Research Group A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266–271.
    1. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383–390.
    1. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145(2):249–256.
    1. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009;23(12):2223–2227.
    1. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495–511.
    1. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.
    1. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2009;125(10):1357–1361.
    1. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina. 2008;28(5):689–695.
    1. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27(4):432–438.
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431.
    1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.
    1. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868–1875.
    1. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2–13.
    1. Zhang XY, Guo XF, Zhang SD, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol. 2014;7(2):355–364.
    1. Solom SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.
    1. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175–1186.
    1. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다